BioNexus Gene Lab Corp. (BGLC) intrinsic value & 10-year financials
BioNexus Gene Lab Corp. (BGLC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 66.2% a year to $7.4M, with an average return on invested capital of -15.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.20
- Market cap
- $21.4M
- Revenue (FY2025)
- $7.4M
- Revenue growth (8-yr CAGR)
- 66.2%
- ROIC (10-yr avg)
- -15.0%
- Free cash flow (FY2025)
- -$1.9M
BGLC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.4M | -$3.0M | — | -$1.9M | -39.9% | -50.1% |
| FY2024 | $9.5M | -$1.6M | -$0.09 | -$2.5M | -16.5% | -24.7% |
| FY2023 | $9.8M | -$2.6M | -$0.17 | -$1.3M | -26.5% | -38.9% |
| FY2022 | $10.9M | -$356.0K | — | $489.9K | -2.7% | -4.5% |
| FY2021 | $13.4M | $751.6K | — | $6.0K | 7.9% | 23.3% |
| FY2020 | $11.4M | $1.1M | — | $131.1K | 11.2% | 51.2% |
| FY2019 | $127.0K | -$246.5K | — | -$230.1K | -217.2% | -85.5% |
| FY2018 | $212.3K | $26.5K | — | -$313.7K | 28.2% | 9.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BioNexus Gene Lab Corp is a consistent compounder, expanding top-line revenue at 66.2% annually over the past decade.
BioNexus Gene Lab Corp has historically struggled to out-earn its cost of capital, averaging just -15.0% ROIC.
BioNexus Gene Lab Corp has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BioNexus Gene Lab Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-5.56 per share.